Trial Profile
An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 30 Dec 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Docetaxel
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms CheckMate-017
- Sponsors Bristol-Myers Squibb
- 16 Jan 2022 This trial has been completed in Ireland (Date of the global end of the trial : 16-Aug-2021), according to European Clinical Trials Database record.
- 03 Dec 2021 Results of Network Meta-Analyses from CHECKMATE 017, KEYNOTE 010, POPLAR and OAK presented at the 24th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 01 Nov 2021 Results published in the Value in Health